# A Study of Docetaxel for Injection (Albumin-bound) in Combination With Bevacizumab in Patients With Ovarian Cancer

> **NCT05325229** · PHASE2 · UNKNOWN · sponsor: **CSPC ZhongQi Pharmaceutical Technology Co., Ltd.** · enrollment: 94 (estimated)

## Conditions studied

- Platinum-resistant Recurrent Ovarian Cancer

## Interventions

- **DRUG:** Docetaxel for injection (Albumin-bound)
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT05325229
- **Lead sponsor:** CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-08-18
- **Primary completion:** 2024-12
- **Final completion:** 2024-12
- **Target enrollment:** 94 (ESTIMATED)
- **Last updated:** 2022-10-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05325229

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05325229, "A Study of Docetaxel for Injection (Albumin-bound) in Combination With Bevacizumab in Patients With Ovarian Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05325229. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*